Drug intelligence / Profile preview

TTI-200.7

Development stage: Preclinical
Lead developer: Pfizer
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

TTI-200.7 is a CD200-specific monoclonal antibody agonist developed by Trillium Therapeutics. This technology was originally licensed from University Health Network (UHN) and The Hospital for Sick Children (SickKids). The drug is designed to prevent the host immune system from attacking transplanted stem cells, with the aim of improving hematopoietic stem cell engraftment.

Targets

CD200R1 (CD200 receptor 1)

Beyond the preview

Go deeper on TTI-200.7.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TTI-200.7.

Explore the full profile